Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer

详细信息    查看全文

• 作者：Yuan-Yu Wang (1)
  Li Li (2)
  Zhong-Sheng Zhao (2)
  Hui-Ju Wang (3)
  
• 关键词：Gastric cancer ; Kinesin II ; associated protein ; TIMP metallopeptidase inhibitor 1 ; Stanniocalcin 2
• 刊名：World Journal of Surgical Oncology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：11
• 期：1
• 全文大小：307KB
• 参考文献：1. Zhan WH, Han FH: Surgical therapy of gastric cancer in china. / J Pract Oncol 2008, 23:91-3.
  2. Ghossein RA, Rosai J: Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. / Cancer 1996, 78:10-6. CrossRef
  3. Pelkey TJ, Frierson HF Jr, Bruns DE: Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. / Clin Chem 1996, 42:1369-381.
  4. Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, Pinto E: Prognostic significance of CEA, CA 19- and CA 72- preoperative serum levels in gastric carcinoma. / Oncology 1999, 57:55-2. CrossRef
  5. Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. / Int J Cancer 2005, 113:198-06. CrossRef
  6. Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A, Giordano C: BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. / Endocr Relat Cancer 2011, 18:669-85. CrossRef
  7. Raulic S, Ramos-Valdes Y, DiMattia GE: Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro. / J Endocrinol 2008, 197:517-29. CrossRef
  8. Kita Y, Mimori K, Iwatsuki M, Yokobori T, Ieta K, Tanaka F, Ishii H, Okumura H, Natsugoe S, Mori M: STC2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma. / Ann Surg Oncol 2011, 18:261-72. CrossRef
  9. Ieta K, Tanaka F, Yokobori T, Kita Y, Haraguchi N, Mimori K, Kato H, Asao T, Inoue H, Kuwano H, Mori M: Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. / Int J Cancer 2009, 125:926-31. CrossRef
  10. Yokoe T, Toiyama Y, Okugawa Y, Tanaka K, Ohi M, Inoue Y, Mohri Y, Miki C, Kusunoki M: KAP1 is associated with peritoneal carcinomatosis in gastric cancer. / Ann Surg Oncol 2010, 17:821-28. CrossRef
  11. Wang YY, Ye ZY, Zhao ZS, Tao HQ, Chu YQ: High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer. / Ann Surg Oncol 2010, 17:89-7. CrossRef
  12. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E: Circulating microRNAs in plasma of patients with gastric cancers. / Br J Cancer 2010, 102:1174-179. CrossRef
  13. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. / CA Cancer J Clin 2007, 57:43-6. CrossRef
  14. Genta RM: Screening for gastric cancer: does it make sense? / Aliment Pharmacol Ther 2004, 20:42-7. CrossRef
  15. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F: Clinical utility of CEA, CA 19-, and CA 72- in the follow-up of patients with resectable gastric cancer. / Am J Surg 2001, 181:16-9. CrossRef
  16. Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, Iwashige H, Tokushige M, Watanabe T, Takao S, Aikou T: Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19- levels in gastric cancer. / J Clin Gastroenterol 2001, 32:41-4. CrossRef
  17. Gaspar MJ, Arribas I, Coca MC, Díez-Alonso M: Prognostic value of carcinoembryonic antigen, CA 19- and CA 72- in gastric carcinoma. / Tumour Biol 2001, 22:318-22. CrossRef
  18. O’Sullivan GC, Collins JK, Kelly J, Morgan J, Madden M, Shanahan F: Micrometastases: marker of metastatic potential or evidence of residual disease? / Gut 1997, 40:512-15.
  19. Jeffery N, McLean MH, El-Omar EM, Murray GI: The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. / Histopathology 2009, 54:820-28. CrossRef
  20. Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR: Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. / Ann Surg Oncol 2007, 14:3460-471. CrossRef
  21. Kebebew E, Peng M, Reiff E, McMillan A: Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. / Cancer 2006, 106:2592-597. CrossRef
  22. Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H: Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and ? in patients with malignant melanoma. / J Dermatol 2008, 35:206-14. CrossRef
  23. Law AY, Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. / Exp Cell Res 2010, 316:466-76. CrossRef
  24. Law AY, Wong CK: Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. / Exp Cell Res 2010, 316:3425-434. CrossRef
  25. Meyer HA, T?lle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, Gaspert A, Johannsen M, Jung K, Kristiansen G: Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. / Eur Urol 2009, 55:669-78. CrossRef
  26. Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS, Isacke CM: Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. / Clin Cancer Res 2007, 13:3164-173. CrossRef
  27. Wang C, Rauscher FJ 3rd, Cress WD, Chen J: Regulation of E2F1 function by the nuclear corepressor KAP1. / J Biol Chem 2007, 282:29902-9909. CrossRef
  28. Tanaka K, Arao T, Maegawa M, Matsumoto K, Kaneda H, Kudo K, Fujita Y, Yokote H, Yanagihara K, Yamada Y, Okamoto I, Nakagawa K, Nishio K: SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. / Int J Cancer 2009, 124:1072-080. CrossRef
  29. Wang L, Yang M, Shan L, Qi L, Chai C, Zhou Q, Yao K, Wu H, Sun W: The role of SPARC protein expression in the progress of gastric cancer. / Pathol Oncol Res 2012, 18:697-02. CrossRef
  30. Zhao ZS, Wang YY, Chu YQ, Ye ZY, Tao HQ: SPARC is associated with gastric cancer progression and poor survival of patients. / Clin Cancer Res 2010, 16:260-68. CrossRef
  31. Haakensen VD, Bj?ro T, Lüders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, B?rresen-Dale AL, Helland ?: Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas. / BMC Cancer 2011, 11:332. CrossRef
  
• 作者单位：Yuan-Yu Wang (1)
  Li Li (2)
  Zhong-Sheng Zhao (2)
  Hui-Ju Wang (3)
  
  1. Department of Gastrointestinal Surgery, Zhejiang Provincial People’s Hospital, 158 shangtang road, Hangzhou, Zhejiang, 310014, PR China
  2. Department of Pathology, Zhejiang Provincial People’s Hospital, 158 shangtang road, Hangzhou, Zhejiang, 310014, PR China
  3. Key Laboratory of Gastroenterology of Zhejiang Province, 158 shangtang road, Hangzhou, Zhejiang, 310014, PR China
  

文摘

Background We examined preoperative kinesin II-associated protein (KAP1), TIMP metallopeptidase inhibitor 1 (TIMP1) and stanniocalcin 2 (STC2) expression levels in patients with gastric cancers to assess their clinical application for diagnosing and monitoring diseases. Methods Real-time reverse transcription-polymerase chain reaction was used to detect the expression levels of KAP1, TIMP1, STC2, talin 2 (TLN2), sushi-repeat-containing protein, X-linked 2 (SRPX2) and secreted protein, acidic, cysteine-rich (SPARC) in the patients-peripheral blood karyocytes. The data were analyzed with receiver operating characteristics (ROC) curves. Results A total of 112 patients with gastric cancer, 42 patients with recurrence and 107 healthy volunteers were recruited. There were significant correlations between KAP1, TIMP1 and STC2 levels, and TNM tumor stages and distant metastases. The area under the ROC curves (AUC) of KAP1 was 0.803?±-.040 (P--.0001), the AUC of TIMP1 was 0.767?±-.043 (P--.0001) and the AUC of STC2 was 0.769?±-.045 (P--.0001), thus differentiating preoperative gastric cancer patients from healthy volunteers by ROC curve analysis. The AUC of STC2 was 0.739?±-.070 (P--.004) and the AUC of KAP1 was 0.418?±-.088 (P--.319), thus differentiating recurrence of gastric cancer from healthy volunteers by ROC curve analysis. High TIMP1 and STC2 expression levels were suspected to be poor prognostic factors of disease recurrence in patients with gastric cancer. Conclusions KAP1, TIMP1 and STC2 expression levels may be potential biomarkers for the screening, diagnosis, prognosis and surveillance of gastric cancer.